XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

What happened: XBiotech (NASDAQ: XBIT) reported positive final Phase II efficacy results from the investigator-sponsored TASKIN trial of vilamakitug (XB2001) added to standard chemotherapy in refractory metastatic colorectal cancer. Why it matters: The principal investigator cited the magnitude of benefit in right-sided colorectal cancers, a historically aggressive subset, and the company said the biomarker-anchored population provides a focused direction toward registrational development.

XBiotech (NASDAQ: XBIT) reported positive final Phase II efficacy results from the investigator-sponsored TASKIN trial of vilamakitug (XB2001) added to standard chemotherapy in refractory metastatic colorectal cancer.

The principal investigator cited the magnitude of benefit in right-sided colorectal cancers, a historically aggressive subset, and the company said the biomarker-anchored population provides a focused direction toward registrational development.